Sugi Predict

Sugi Predict / Compounds / SCHEMBL3379211

SCHEMBL3379211

SCHEMBL3379211

CCOC(=O)Cc1nc2ccc(N(C)C)cc2[nH]1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSD17B10 Q99714 2/20 0.64
▸ SIRT2 Q8IXJ6 1/20 0.53
▸ SIRT1 Q96EB6 1/20 0.53
▸ CHEK1 O14757 1/20 0.50
▸ MAPT P10636 3/20 0.49
▸ KDM4E B2RXH2 1/20 0.46
▸ ALDH1A1 P00352 1/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ GRIN1 Q05586 1/20 0.42
▸ GRIN2B Q13224 1/20 0.42
▸ PRMT5 O14744 1/20 0.41
▸ WDR77 Q9BQA1 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ AKT1 P31749 1/20 0.41
▸ KMT2A Q03164 3/20 0.40
▸ MEN1 O00255 2/20 0.40
▸ MAOB P27338 1/20 0.40
▸ BRD4 O60885 1/20 0.40
▸ NPC1 O15118 1/20 0.40
▸ PKN1 Q16512 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3379207 0.90 HSD17B10 (0.64) HSD17B10SIRT2SIRT1CHEK1MAPT
SCHEMBL3379881 0.87 HSD17B10 (0.58) HSD17B10SIRT2SIRT1CHEK1MAPT
SCHEMBL31735534 0.84 HSD17B10 (0.71) HSD17B10CHEK1MAPTKDM4EALDH1A1
SCHEMBL3840420 0.84 HSD17B10 (0.71) HSD17B10CHEK1MAPTKDM4EALDH1A1
SCHEMBL3381346 0.83 HSD17B10 (0.62) HSD17B10SIRT2SIRT1CHEK1MAPT
SCHEMBL7357590 0.82 HSD17B10 (0.67) HSD17B10CHEK1MAPTKDM4EALDH1A1
SCHEMBL38662484 0.82 HSD17B10 (0.67) HSD17B10CHEK1MAPTKDM4EALDH1A1
SCHEMBL3383861 0.81 HSD17B10 (0.66) HSD17B10SIRT2SIRT1CHEK1MAPT
SCHEMBL7087113 0.79 HSD17B10 (0.57) HSD17B10SIRT2SIRT1CHEK1MAPT
SCHEMBL3730393 0.79 HSD17B10 (0.63) HSD17B10SIRT2SIRT1CHEK1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2573079-A2 Benzimidazole quinolinones and uses thereof Novartis Vaccines and Diagnostics, Inc. (US) 2013-03-27 — — EP disclosed
EP-1497287-B1 Quinoline derivatives in combination with 5-FU or CPT-11 for use in the treatment of cancer NOVARTIS VACCINES & DIAGNOSTIC (US) 2010-11-24 — — EP disclosed
US-7825132-B2 Inhibition of FGFR3 and treatment of multiple myeloma NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2010-11-02 — — US disclosed
US-20100184754-A1 QUINOLINONE DERIVATIVES NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2010-07-22 — — US disclosed
US-20090281100-A1 Benzimidazole quinolinones and uses thereof BARSANTI PAUL A 2009-11-12 — — US disclosed
EP-1313734-B1 AZA HETEROCYCLIC DERIVATIVES AND THEIR THERAPEUTIC USE NOVARTIS VACCINES & DIAGNOSTIC (US) 2009-11-11 — — EP disclosed
US-7598268-B2 Quinolinone derivatives NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2009-10-06 — — US disclosed
EP-1539754-A4 BENZIMIDAZOLE QUINOLINONES AND USES THEREOF NOVARTIS VACCINES & DIAGNOSTIC (US) 2009-02-25 — — EP disclosed
US-7470709-B2 Benzimidazole quinolinones and uses thereof NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2008-12-30 — — US disclosed
US-7368459-B2 Heterocyclic compounds CHIRON CORPORATION (US) 2008-05-06 — — US disclosed
WO-2003087095-A1 QUINOLINONE DERIVATIVES CHIRON CORPORATION (US) 2003-10-23 — — WO disclosed
US-20030158224-A1 Quinolinone derivatives CHIRON CORPORATION 2003-08-21 — — US disclosed
US-6605617-B2 Treating a patient in need of an inhibitor of vascular endothelial growth factor receptor tyrosine kinase CHIRON CORPORATION 2003-08-12 — — US disclosed
EP-1317442-A1 QUINOLINONE DERIVATIVES AS TYROSINE KINASE INHIBITORS CHIRON CORPORATION (US) 2003-06-11 — — EP disclosed
EP-1313734-A2 AZA HETEROCYCLIC DERIVATIVES AND THEIR THERAPEUTIC USE CHIRON CORPORATION (US) 2003-05-28 — — EP disclosed
US-20030028018-A1 Quinolinone derivatives CHIRON COPORATION 2003-02-06 — — US disclosed
US-20020107392-A1 Quinolinone derivatives NOVARTIS AG (CH) 2002-08-08 — — US disclosed
US-20020103230-A1 Heterocyclic compounds CHIRON CORPORATION 2002-08-01 — — US disclosed
WO-2002022598-A1 QUINOLINONE DERIVATIVES AS TYROSINE KINASE INHIBITORS CHIRON CORPORATION (US) 2002-03-21 — — WO disclosed
WO-2002018383-A2 AZA HETEROCYCLIC DERIVATIVES AND THEIR THERAPEUTIC USE CHIRON CORPORATION (US) 2002-03-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020103230-A1 Heterocyclic compounds SLCO2A1, SLCO1B1, SLCO2B1 HSD17B10 793/4885SIRT2 721/4885SIRT1 548/4885
US-20090281100-A1 Benzimidazole quinolinones and uses thereof GAA, ALPI, IL4I1 HSD17B10 754/4885SIRT2 1864/4885SIRT1 1681/4885
US-20030028018-A1 Quinolinone derivatives SLCO1B1, SLCO1B3, SLCO1A2 HSD17B10 540/4885SIRT2 862/4885SIRT1 1316/4885
US-20030158224-A1 Quinolinone derivatives SLCO1B1, SLCO1B3, SLCO1A2 HSD17B10 540/4885SIRT2 862/4885SIRT1 1316/4885
US-20020107392-A1 Quinolinone derivatives SLCO1B1, SLCO1B3, SLCO1A2 HSD17B10 540/4885SIRT2 862/4885SIRT1 1316/4885
US-20100184754-A1 QUINOLINONE DERIVATIVES SLCO1B1, SLCO1B3, SLCO1A2 HSD17B10 498/4885SIRT2 832/4885SIRT1 1474/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.